Heparan sulfate: <i>In vitro</i> and <i>in vivo</i> proof of efficacy of this new therapeutic strategy for halting Alzheimer disease‐related tauopathy development
Auriane Maïza(Centre National de la Recherche Scientifique), Dulce Papy-García(Université Paris-Est Créteil), Estelle Jospin(Centre National de la Recherche Scientifique), Mohand Ouidir Ouidja(Centre National de la Recherche Scientifique), David G. Fernig(University of Liverpool), Alexandre Fifre(Centre National de la Recherche Scientifique), Kithika Ramakrishnan(University of Liverpool), Aida Muntsant Soria(Universitat Autònoma de Barcelona), Lydia Giménez‐Llort(Universitat Autònoma de Barcelona), Xavier Laffray(Centre National de la Recherche Scientifique), Yong Li(Yangzhou University), Sandrine Chantepie‐Laborde(Université Paris-Est Créteil), Ivan Ramos(Université Paris-Est Créteil), Gael Le Douaron(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
|Proceedings of the National Academy of Sciences|2013|864
Heparan Sulfate Is a Cellular Receptor for Purified Infectious Prions
|Journal of Biological Chemistry|2005|175
Transport of Fibroblast Growth Factor 2 in the Pericellular Matrix Is Controlled by the Spatial Distribution of Its Binding Sites in Heparan Sulfate
|PLoS Biology|2012|133
Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease
|Parkinsonism & Related Disorders|2001|131
The 37‐kDa/67‐kDa Laminin Receptor Acts as a Receptor for Infectious Prions and Is Inhibited by Polysulfated Glycanes
|The Journal of Infectious Diseases|2006|126